Telefon:
+49 (0)241 95 163 153
Fax:
+49 (0)241 95 163 155
E-Mail:
orders@antikoerper-online.de

Rekombinanter ADAM17 Antikörper

ADAM17 Reaktivität: Human Func Wirt: Human Monoclonal D1(A12) unconjugated Recombinant Antibody
Produktnummer ABIN5564275
  • Target Alle ADAM17 Antikörper anzeigen
    ADAM17 (ADAM Metallopeptidase Domain 17 (ADAM17))
    Antikörpertyp
    Recombinant Antibody
    Reaktivität
    • 103
    • 52
    • 50
    • 4
    • 4
    • 4
    • 1
    Human
    Wirt
    • 89
    • 13
    • 1
    • 1
    • 1
    Human
    Klonalität
    • 82
    • 23
    Monoklonal
    Konjugat
    • 47
    • 10
    • 7
    • 5
    • 4
    • 4
    • 3
    • 3
    • 3
    • 3
    • 3
    • 3
    • 1
    • 1
    • 1
    • 1
    • 1
    • 1
    • 1
    • 1
    • 1
    • 1
    Dieser ADAM17 Antikörper ist unkonjugiert
    Applikation
    • 78
    • 47
    • 38
    • 15
    • 14
    • 13
    • 10
    • 10
    • 9
    • 4
    • 4
    • 4
    • 3
    • 2
    • 1
    Functional Studies (Func)
    Spezifität
    Recognizes the catalytic and non-catalytic domain of human ADAM17 (TACE) through its variable light (VL) domain and variable heavy (VH) domain, respectively. Does not bind recombinant mouse ADAM17 ectodomain.
    Kreuzreaktivität
    Human
    Reinheit
    >95 % (SDS-PAGE)
    Endotoxin-Niveau
    <0.001EU/μg
    Immunogen
    Recombinant human ADAM17 (TACE) ectodomain tagged to biotin.
    Klon
    D1(A12)
    Isotyp
    IgG1
    Top Product
    Discover our top product ADAM17 Primärantikörper
  • Kommentare

    This cross-domain human antibody is a selective ADAM17 (TACE) antagonist and provides a unique alternative to small molecule metalloprotease inhibition. ADAM multidomain topology was exploited by first isolating an inhibitory human antibody (D1) that bound ADAM17-specific non-catalytic regions exclusively through its variable heavy (VH) domain. A D1-VH biased scFv phage-display library was then used to selectively isolate a new variable light (VL) chain that could simultaneously bind to the ADAM17 catalytic domain.

    Beschränkungen
    Nur für Forschungszwecke einsetzbar
  • Format
    Liquid
    Konzentration
    Lot specific
    Buffer
    In PBS.
    Konservierungsmittel
    Without preservative
    Lagerung
    4 °C,-20 °C
    Informationen zur Lagerung
    Short Term Storage: +4°C
    Long Term Storage: -20°C
    Stable for at least 1 year after receipt when stored at -20°C.
    Haltbarkeit
    12 months
  • Target
    ADAM17 (ADAM Metallopeptidase Domain 17 (ADAM17))
    Andere Bezeichnung
    ADAM17 (ADAM17 Produkte)
    Synonyme
    ADAM18 antikoerper, CD156B antikoerper, CSVP antikoerper, NISBD antikoerper, TACE antikoerper, CD156b antikoerper, Tace antikoerper, adam17 antikoerper, si:dkey-81b15.2 antikoerper, adam18 antikoerper, cd156b antikoerper, csvp antikoerper, tace antikoerper, fc20b01 antikoerper, wu:fc20b01 antikoerper, zgc:63886 antikoerper, ADAM metallopeptidase domain 17 antikoerper, a disintegrin and metallopeptidase domain 17 antikoerper, ADAM metallopeptidase domain 17b antikoerper, ADAM metallopeptidase domain 17 L homeolog antikoerper, ADAM metallopeptidase domain 17a antikoerper, ADAM17 antikoerper, Adam17 antikoerper, adam17b antikoerper, adam17.L antikoerper, adam17a antikoerper
    Hintergrund
    ADAM17 (Disintegrin and metalloproteinase domain-containing protein 17), also called TACE (Tumor necrosis factor-alpha-converting enzyme) is the prototype of the ADAM family of ectodomain shedding proteases (sheddase). ADAM17 is understood to be involved in the processing of TNF-alpha at the surface of the cell and from within the intracellular membranes of the trans-Golgi network. This process involves the cleavage and release of a soluble ectodomain from membrane-bound pro-proteins (such as pro-TNF-alpha) and is of known physiological importance. ADAM17 is responsible for the processing of a diverse variety of membrane-anchored cytokines, cell adhesion molecules, receptors, ligands and enzymes, including cleaving epidermal growth factor receptor (EGFR) ligands and extracellular Notch1. The proteolytic cleavage is an indispensable activation event for many of these substrates, ADAM17 has emerged as an attractive therapeutic target for the treatment of inflammatory diseases (e.g. rheumatoid arthritis) or inflammation associated cancer.
    UniProt
    P78536
    Pathways
    Notch Signalweg, EGFR Signaling Pathway, Neurotrophin Signalübertragung, Response to Growth Hormone Stimulus
Sie sind hier:
Kundenservice